Drugs / IMT504
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06312423 | Feb → Aug 2024 | immune system disorder | Ministry of Public Health of the Province of La Rioja | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMT504 | “The first group will be administered subcutaneously with a single dose of 20 mg of IMT504.” NCT06312423 ↗ |
| Modality | Oligonucleotide (other) | “IMT504 Phosphorothioate Oligonucleotide, an immunomodulator and tissue repair inducer” NCT06312423 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT06312423 ↗ |